The oblivion of ignoring the obvious
This article was originally published in Scrip
Executive Summary
Several very large pharmaceutical companies each of which boasts a long history of competence in dealing with government regulatory bodies have somehow failed to take the hint with regard to the requirements of the German reimbursement system.